A. Brown

发表

Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.

M. Andrews, A. Brown, J. Chiva, 2009, Bioorganic & medicinal chemistry letters.

Design of monoamine reuptake inhibitors: SSRIs, SNRIs and NRIs

M. Andrews, A. Brown, P. Fish, 2008 .

Ion channels as therapeutic targets: a drug discovery perspective.

R. M. Owen, A. Brown, E. Stevens, 2013, Journal of medicinal chemistry.

Sulfonamides as selective oestrogen receptor β agonists.

A. Brown, Malcolm C. Mackenny, A. Bent, 2011, Bioorganic & medicinal chemistry letters.

The discovery of long acting β2-adrenoreceptor agonists

Alan Daniel Brown, Mark E. Bunnage, M. Bunnage, 2007 .

The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain.

A. Brown, E. Stevens, J. Warmus, 2019, Bioorganic & medicinal chemistry.

Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice

A. Brown, H. Davis, M. McCluskie, 2013, PloS one.

Synthesis of 1,2,5,6-Tetrahydro-3-pyridinylalanine: A Key Intermediate in the Preparation of Thrombin Inhibitor UK-239,326

K. James, A. Brown, P. Fish, 2008 .

Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.

M. Andrews, A. Brown, P. Fish, 2011, Bioorganic & medicinal chemistry letters.

7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.

A. Brown, P. Fish, Lee R. Roberts, 2009, Bioorganic & medicinal chemistry letters.

Metal-free coupling of saturated heterocyclic sulfonylhydrazones with boronic acids.

A. Brown, S. Ley, D. Blakemore, 2014, The Journal of organic chemistry.

First asymmetric desymmetrisation of a centrosymmetric molecule: CBS reduction of a 2-pyridone (4 + 4)-photodimer derivative

A. Brown, A. Spivey, C. Frampton, 1999 .

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

P. A. Bradley, Brian E Marron, Ian K Gurrell, 2017, Journal of medicinal chemistry.

Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

M. Bunnage, David A. Price, A. Brown, 2010, Journal of medicinal chemistry.

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists.

David W. Gordon, M. Andrews, A. Brown, 2009, Bioorganic & medicinal chemistry letters.

Palladium catalysed cyclisation-cyclopropanation and cyclisation - anion capture processes of vinyl triflates

R. Grigg, A. Brown, M. Thornton-Pett, 1994 .

Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity.

A. Brown, L. Maes, G. Whitlock, 2015, Journal of medicinal chemistry.

N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.

A. Brown, P. Fish, G. Whitlock, 2006, Bioorganic & medicinal chemistry letters.

Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonists.

A. Brown, Malcolm C. Mackenny, G. McMurray, 2013, Bioorganic & medicinal chemistry letters.

Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans.

Steven W. Martin, A. Brown, D. Fradet, 2010, Journal of medicinal chemistry.

Vaccin peptidique ige ch3

D. Gervais, A. Brown, B. Champion, 2009 .

Designing drugs for the treatment of female sexual dysfunction.

A. Brown, J. Blagg, D. Reynolds, 2007, Drug discovery today.

Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence.

John P. Overington, K. James, A. Brown, 2002, Journal of medicinal chemistry.

Small molecule inhibitors of IgE synthesis.

A. Brown, M. Lansdell, G. Maw, 2006, Bioorganic & medicinal chemistry letters.

Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.

Robert P. DePianta, V. Shanmugasundaram, A. Brown, 2014, Journal of medicinal chemistry.

The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists.

Mark E Bunnage, M. Bunnage, David A. Price, 2008, Bioorganic & medicinal chemistry letters.

Discovery and optimisation of potent and highly subtype selective Nav1.8 inhibitors with reduced cardiovascular liabilities

Tanya L Hay, A. Brown, E. Stevens, 2016 .

Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.

A. Brown, W. Klute, Duncan C Miller, 2011, Bioorganic & medicinal chemistry letters.

Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.

A. Brown, W. Klute, Andrew Calabrese, 2009, Bioorganic & medicinal chemistry letters.

The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.

Mark E Bunnage, M. Bunnage, David A. Price, 2007, Bioorganic & medicinal chemistry letters.

Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes.

Brian E Marron, Neil A Castle, Rubben Torella, 2017, Bioorganic & medicinal chemistry letters.

SAR mining and its application to the design of TRPA1 antagonists

Sarah Elizabeth Skerratt, James Edward John Mills, Alan Daniel Brown, 2012 .

Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.

A. Brown, Andrew Calabrese, L. Watson, 2010, Bioorganic & medicinal chemistry letters.